Global Markets Direct’s, ‘Secondary Hyperparathyroidism – Pipeline Review, H1 2014′, provides an overview of the Secondary Hyperparathyroidism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Secondary Hyperparathyroidism and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Secondary Hyperparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Secondary Hyperparathyroidism pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Secondary Hyperparathyroidism Overview 7
Therapeutics Development 8
Pipeline Products for Secondary Hyperparathyroidism - Overview 8
Pipeline Products for Secondary Hyperparathyroidism - Comparative Analysis 9
Secondary Hyperparathyroidism - Therapeutics under Development by Companies 10
Secondary Hyperparathyroidism - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Secondary Hyperparathyroidism - Products under Development by Companies 15
Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development 16
Amgen Inc. 16
Nektar Therapeutics 17
Astellas Pharma Inc. 18
Mitsubishi Tanabe Pharma Corporation 19
OPKO Health, Inc. 20
NPS Pharmaceuticals, Inc. 21
Deltanoid Pharmaceuticals Inc. 22
Secondary Hyperparathyroidism - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
cinacalcet hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
velcalcetide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
calcifediol MR - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
lunacalcipol - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CTAP-201 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
DP-001 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ASP-7991 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
velcalcetide - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
MT-4580 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
velcalcetide - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
NKTR-228 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VS-105 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
VS-110 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CTA-091 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Calcimimetic-18 for Secondary Hyperparathyroidism - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
VS-411 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Secondary Hyperparathyroidism - Recent Pipeline Updates 56
Secondary Hyperparathyroidism - Dormant Projects 64
Secondary Hyperparathyroidism - Product Development Milestones 65
Featured News & Press Releases 65
Dec 19, 2013: OPKO Completes Patient Recruitment in Second Phase 3 Trial of Rayaldy 65
Aug 15, 2013: OPKO Surpasses 50% Enrollment in Second Phase 3 Trial of Rayaldy 65
Jun 27, 2013: Kyowa Hakko Kirin Files Application Seeking Approval For Additional Indication For Regpara Tablets 25mg And 75mg 66
May 23, 2013: Opko Health Surpasses 50% Enrollment In First Phase III Trial Of Rayaldy For Treatment Of Secondary Hyperparathyroidism 66
Mar 07, 2013: Health Canada Cautions Against Use Of Amgen's Sensipar In Children 67
Feb 26, 2013: Amgen's Pediatric Clinical Trial Of Sensipar Suspended By FDA Following Death Of Patient 68
Jan 26, 2013: AbbVie Files Patent Infringement Lawsuit Against Sun Pharma Over Zemplar 68
Nov 03, 2012: Amgen Announces Results From Phase III EVOLVE Trial Of Sensipar/Mimpara In Patients With Secondary Hyperparathyroidism And Chronic Kidney Disease Receiving Dialysis 69
Sep 20, 2012: Cytochroma Initiates Phase III Study Of CTAP101 Capsules In Chronic Kidney Disease Patients 70
Aug 28, 2012: Rockwell Medical Receives Canadian Patent For SFP Formulation For Iron-Delivery In Hemodialysis Patients 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables

Number of Products under Development for Secondary Hyperparathyroidism, H1 2014 8
Number of Products under Development for Secondary Hyperparathyroidism - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Secondary Hyperparathyroidism - Pipeline by Amgen Inc., H1 2014 16
Secondary Hyperparathyroidism - Pipeline by Nektar Therapeutics, H1 2014 17
Secondary Hyperparathyroidism - Pipeline by Astellas Pharma Inc., H1 2014 18
Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corporation., H1 2014 19
Secondary Hyperparathyroidism - Pipeline by OPKO Health, Inc., H1 2014 20
Secondary Hyperparathyroidism - Pipeline by NPS Pharmaceuticals, Inc., H1 2014 21
Secondary Hyperparathyroidism - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2014 22
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Stage and Target, H1 2014 26
Number of Products by Stage and Mechanism of Action, H1 2014 28
Number of Products by Stage and Route of Administration, H1 2014 30
Number of Products by Stage and Molecule Type, H1 2014 32
Secondary Hyperparathyroidism Therapeutics - Recent Pipeline Updates, H1 2014 56
Secondary Hyperparathyroidism - Dormant Projects, H1 2014 64

List of Figures

Number of Products under Development for Secondary Hyperparathyroidism, H1 2014 8
Number of Products under Development for Secondary Hyperparathyroidism - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Top 10 Target, H1 2014 24
Number of Products by Stage and Top 10 Target, H1 2014 25
Number of Products by Top 10 Mechanism of Action, H1 2014 27
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 28
Number of Products by Top 10 Route of Administration, H1 2014 29
Number of Products by Stage and Top 10 Route of Administration, H1 2014 30
Number of Products by Top 10 Molecule Type, H1 2014 31
Number of Products by Stage and Top 10 Molecule Type, H1 2014 32